IGFL2 and cancer: We assessed the proportion of immune matrix components using three scores, StromalScore, ImmuneScore and ESTIMATEScore, showed that 24 cancers were positively correlated with IGFL2 expression, including CHAD (r = 0.39, 0.35, 0.40), LUSC (r = 0.46, 0.21, 0.34), and THCA (r = 0.51, 0.44, 0.50), p < 0.001 (Fig. 5A), indicating that IGFL2 expression was closely associated with the degree of immune infiltration in cancer.